Guardant Health Investor Presentation

AstraZeneca Partnership: Guardant found more patients who may benefit from combination immunotherapy Evaluable Patients for TMB analysis Guardant TMB High Overall Survival 460 Tissue TMB Annals of Oncology, Volume 29, Issue suppl_10, 1 December 2018 809 GUARDANT OMNI Probability of OS Durvalumab + Durvalumab tremelimumab Chemotherapy 1.0. 0.8- MOS, months (95% CI) HR vs CT* (95% CI) (n=111) (n=106) 11.0 16.5 (7.8-16.1) (10.3-22.9) 0.80 0.62 (0.588-1.077) (0.451-0.855) (n=102) 10.5 (8.8-12.4) 0.6' 39% 0.4- 0.2- 18% 0.0 03 6 9 12 15 18 21 24 27 30 33 36 Time from randomisation (months) 17 GUARDANT

View entire presentation